{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:36Z","timestamp":1790144196829,"version":"4.0.1"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,7]]},"abstract":" PURPOSE: Tamoxifen is the most commonly prescribed adjuvant therapy for women with breast cancer. It has agonist activity on the endometrium and is associated with an increased risk of endometrial cancer. The aim of this study was to evaluate whether screening with transvaginal ultrasound (TV USS) with or without hysteroscopy is worthwhile. <\/jats:p> PATIENTS AND METHODS: A total of 487 women with breast cancer, 357 treated with tamoxifen and 130 controls, were screened with TV USS, and endometrial thickness was measured. Women with thickened endometrium underwent outpatient hysteroscopy. <\/jats:p> RESULTS: Length of time on tamoxifen ranged from 5 to 191 months (mean, 66 months), and endometrial thickness ranged from 1 to 38 mm (mean, 7.3 mm). Women treated with tamoxifen had significantly thicker endometrium than did controls (P < .0001). There was a statistically significant (P < .0001) positive correlation between length of time on tamoxifen and endometrial thickness. One hundred forty-five women had endometrium greater than 5 mm on USS, and 134 underwent successful outpatient hysteroscopy, 61 of whom had atrophic endometrium, resulting in a 46% false-positive scan rate. The remaining women all had benign features to explain the USS findings. <\/jats:p> CONCLUSION: TV USS detects a high incidence (41%) of apparent endometrial thickening in women treated with tamoxifen, although 46% had atrophic endometrium on further assessment, and none of the remaining asymptomatic women had significant lesions. Length of time on tamoxifen relates to endometrial thickening as measured by TV USS. TV USS is a poor screening tool because of the high false-positive rate. The low frequency of significant findings suggests that endometrial screening in asymptomatic women is not worthwhile. <\/jats:p>","DOI":"10.1200\/jco.1999.17.7.2050","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:31:04Z","timestamp":1487917864000},"page":"2050-2050","source":"Crossref","is-referenced-by-count":110,"title":["Investigation of Endometrial Abnormalities in Asymptomatic Women Treated With Tamoxifen and an Evaluation of the Role of Endometrial Screening"],"prefix":"10.1200","volume":"17","author":[{"given":"C.D.B.","family":"Love","sequence":"first","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. B.","family":"Muir","sequence":"additional","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Scrimgeour","sequence":"additional","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.F.","family":"Leonard","sequence":"additional","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dillon","sequence":"additional","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Dixon","sequence":"additional","affiliation":[{"name":"From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-2050","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R2-2050","unstructured":"Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237,1985-238,"},{"key":"R3-2050","doi-asserted-by":"crossref","unstructured":"Malfento JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 84:82,1990-84,","DOI":"10.1016\/0090-8258(90)90404-9"},{"key":"R4-2050","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900401)65:7<1463::AID-CNCR2820650702>3.0.CO;2-S"},{"key":"R5-2050","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.16"},{"key":"R6-2050","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.7.527"},{"key":"R7-2050","doi-asserted-by":"crossref","unstructured":"Fornander T, Cedermask B, Mattson A, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 21:117,1989-119,","DOI":"10.1016\/S0140-6736(89)91141-0"},{"key":"R8-2050","unstructured":"Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med 90:207,1990-208,"},{"key":"R9-2050","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92692-1"},{"key":"R11-2050","doi-asserted-by":"publisher","DOI":"10.1016\/0301-5629(86)90336-4"},{"key":"R12-2050","doi-asserted-by":"publisher","DOI":"10.1007\/BF01805762"},{"key":"R13-2050","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb21761.x"},{"key":"R14-2050","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.513"},{"key":"R15-2050","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689674"},{"key":"R16-2050","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951115)76:10+<2044::AID-CNCR2820761323>3.0.CO;2-N"},{"key":"R17-2050","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-199412000-00006"},{"key":"R19-2050","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0064"},{"key":"R20-2050","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1991.tb10342.x"},{"key":"R21-2050","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90250-3"},{"key":"R22-2050","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.2.83"},{"key":"R23-2050","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-199604000-00010"},{"key":"R26-2050","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.160.4.8456669"},{"key":"R27-2050","doi-asserted-by":"crossref","unstructured":"Ciatto S, Cecchini S, Bonardi R, et al: Ultrasonography surveillance of endometrium in breast cancer patients on adjuvant tamoxifen. Lancet 344:60,1994, (letter)","DOI":"10.1016\/S0140-6736(94)91082-0"},{"key":"R28-2050","doi-asserted-by":"crossref","unstructured":"Neven P, De Muylder X, Can Velle Y, et al: Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351:36,1998, (letter)","DOI":"10.1016\/S0140-6736(05)78091-0"},{"key":"R29-2050","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712183372502"},{"key":"R30-2050","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005820115535"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.7.2050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:34:16Z","timestamp":1653514456000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.7.2050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1999,7]]}},"alternative-id":["10.1200\/JCO.1999.17.7.2050"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.7.2050","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,7]]}}}